TELA PE Ratio & Valuation,Is TELA Overvalued

TELA Relative Valuation

TELA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TELA is overvalued; if below, it's undervalued.

Historical Valuation

TELA Bio Inc (TELA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.57 is considered Undervalued compared with the five-year average of -4.32. The fair price of TELA Bio Inc (TELA) is between 2.73 to 8.49 according to relative valuation methord. Compared to the current price of 1.09 USD , TELA Bio Inc is Undervalued By 60.06%.

Relative Value

Fair Zone

2.73-8.49

Current Price：1.09

60.06%

Undervalued

-1.82

-3.07

EV/EBITDA

TELA Bio Inc. (TELA) has a current EV/EBITDA of -3.07. The 5-year average EV/EBITDA is -5.38. The thresholds are as follows: Strongly Undervalued below -9.72, Undervalued between -9.72 and -7.55, Fairly Valued between -3.21 and -7.55, Overvalued between -3.21 and -1.04, and Strongly Overvalued above -1.04. The current Forward EV/EBITDA of -3.07 falls within the Overvalued range.

-2.28

EV/EBIT

TELA Bio Inc. (TELA) has a current EV/EBIT of -2.28. The 5-year average EV/EBIT is -4.23. The thresholds are as follows: Strongly Undervalued below -7.02, Undervalued between -7.02 and -5.62, Fairly Valued between -2.83 and -5.62, Overvalued between -2.83 and -1.43, and Strongly Overvalued above -1.43. The current Forward EV/EBIT of -2.28 falls within the Overvalued range.

0.57

TELA Bio Inc. (TELA) has a current PS of 0.57. The 5-year average PS is 2.87. The thresholds are as follows: Strongly Undervalued below -0.91, Undervalued between -0.91 and 0.98, Fairly Valued between 4.76 and 0.98, Overvalued between 4.76 and 6.65, and Strongly Overvalued above 6.65. The current Forward PS of 0.57 falls within the Undervalued range.

0.00

P/OCF

TELA Bio Inc. (TELA) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.36. The thresholds are as follows: Strongly Undervalued below -18.78, Undervalued between -18.78 and -9.57, Fairly Valued between 8.84 and -9.57, Overvalued between 8.84 and 18.05, and Strongly Overvalued above 18.05. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

TELA Bio Inc. (TELA) has a current P/FCF of 0.00. The 5-year average P/FCF is -5.63. The thresholds are as follows: Strongly Undervalued below -58.74, Undervalued between -58.74 and -32.18, Fairly Valued between 20.92 and -32.18, Overvalued between 20.92 and 47.48, and Strongly Overvalued above 47.48. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

TELA Bio Inc (TELA) has a current Price-to-Book (P/B) ratio of 29.54. Compared to its 3-year average P/B ratio of 14.49 , the current P/B ratio is approximately 103.90% higher. Relative to its 5-year average P/B ratio of 7.16, the current P/B ratio is about 312.76% higher. TELA Bio Inc (TELA) has a Forward Free Cash Flow (FCF) yield of approximately -62.05%. Compared to its 3-year average FCF yield of -39.61%, the current FCF yield is approximately 56.66% lower. Relative to its 5-year average FCF yield of -31.34% , the current FCF yield is about 98.01% lower.

29.54

P/B

Median3y

14.49

Median5y

7.16

-62.05

FCF Yield

Median3y

-39.61

Median5y

-31.34

Competitors Valuation Multiple

The average P/S ratio for TELA's competitors is 2.84, providing a benchmark for relative valuation. TELA Bio Inc Corp (TELA) exhibits a P/S ratio of 0.57, which is -79.82% above the industry average. Given its robust revenue growth of 9.14%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of TELA decreased by 57.58% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 18.96M to 20.69M.

The secondary factor is the Margin Expansion, contributed -24.00%to the performance.

Overall, the performance of TELA in the past 1 year is driven by Revenue Growth. Which is more sustainable.

9.14%

18.96M → 20.69M

Revenue Growth

-24.00%

-54.71 → -41.58

Margin Expansion

-42.72%

-2.25 → -1.29

P/E Change

-57.58%

2.64 → 1.12

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is TELA Bio Inc (TELA) currently overvalued or undervalued?

What is TELA Bio Inc (TELA) fair value?

TELA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of TELA Bio Inc (TELA) is between 2.73 to 8.49 according to relative valuation methord.

How does TELA's valuation metrics compare to the industry average?

What is the current P/B ratio for TELA Bio Inc (TELA) as of Jan 08 2026?

As of Jan 08 2026, TELA Bio Inc (TELA) has a P/B ratio of 29.54. This indicates that the market values TELA at 29.54 times its book value.

What is the current FCF Yield for TELA Bio Inc (TELA) as of Jan 08 2026?

As of Jan 08 2026, TELA Bio Inc (TELA) has a FCF Yield of -62.05%. This means that for every dollar of TELA Bio Inc’s market capitalization, the company generates -62.05 cents in free cash flow.

What is the current Forward P/E ratio for TELA Bio Inc (TELA) as of Jan 08 2026?

As of Jan 08 2026, TELA Bio Inc (TELA) has a Forward P/E ratio of -1.82. This means the market is willing to pay $-1.82 for every dollar of TELA Bio Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for TELA Bio Inc (TELA) as of Jan 08 2026?

As of Jan 08 2026, TELA Bio Inc (TELA) has a Forward P/S ratio of 0.57. This means the market is valuing TELA at $0.57 for every dollar of expected revenue over the next 12 months.

TELA Valuation